Not finding it? Sign in to also search OpenAlex live.
-
External Quality Assessment on Molecular Tumor Profiling with Circulating Tumor DNA-Based Methodologies Routinely Used in Clinical Pathology within the COIN Consortium2024 Clinical Chemistry article Biochemistry, Genetics and Molecular Biology Cancer Genomics and Diagnostics Open access
Paul van der Leest, Pim Rozendal, John W. J. Hinrichs, Carel J.M. van Noesel, Karen Zwaenepoel, Birgit A. L. M. Deiman, +14 more
10citations -
Added value of tumor–stroma ratio to postsurgery circulating tumor DNA and pTN stage in risk stratification of patients with stage III colon cancer treated with adjuvant chemotherapy
Ingrid A. Franken, F. Heilijgers, M.-C.E. Bakker, Carmen Rubio Alarcon, Frederieke H. van der Baan, Margriet Lemmens, +8 more
3citations -
Combined prognostic value of post-surgery circulating tumor DNA and tumor-stroma ratio in patients with stage III colon cancer treated with adjuvant chemotherapy.2025 Journal of Clinical Oncology conference-abstract Medicine Colorectal Cancer Surgical Treatments Open access
Ingrid A. Franken, Floor Heilijgers, Marie-Christine Bakker, Carmen Rubio Alarcon, Nerma Crnovrsanin, Margriet Lemmens, +8 more
3citations -
PARP-inhibitor response evaluation in recurrent epithelial ovarian cancer using circulating tumor DNA and functional HRD testing2026 International Journal of Gynecological Cancer article Medicine PARP inhibition in cancer therapy Open access
Merel Vegter, Lise M. van Wijk, CJH Kramer, M. Jalving, T. Bosse, Dik C. van Gent, +9 more
0citations -
Evaluation of Circulating Tumor DNA as a Liquid Biomarker in Uveal Melanoma2024 Investigative Ophthalmology & Visual Science article Medicine Ocular Oncology and Treatments Open access
Daniël P. de Bruyn, Natasha M. van Poppelen, Tom Brands, Susanne C. van den Boom, Ellis L. Eikenboom, Anja Wagner, +11 more
18citations -
Longitudinal Circulating Tumor DNA–Guided Resistance Analysis During Second-Line Osimertinib Treatment2025 JTO Clinical and Research Reports article Medicine Lung Cancer Treatments and Mutations Open access
Tijmen J.W.T. van der Wel, M. Jebbink, Vincent van der Noort, Ferry Lalezari, Gerrina Ruiter, Jacobus A. Burgers, +8 more
1citations -
Detection of Circulating Tumor DNA for Disease Monitoring in Patients with Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type2024 Journal of Investigative Dermatology article Medicine Cutaneous lymphoproliferative disorders research Open access
Anne M.R. Schrader, Julia van Engeland, Rein Willemze, Joost S.P. Vermaat, Rosanne Ottevanger, Juliette M. Kersten, +7 more
4citations -
151P Baseline circulating tumor DNA (ctDNA) biomarker analysis of patients with human epidermal growth factor receptor 2 (HER2)-overexpressing metastatic non–small cell lung cancer (NSCLC) treated with trastuzumab deruxtecan (T-DXd)
E.F. Smit, Enriqueta Felip, D. Uprety, Misako Nagasaka, Kazuhiko Nakagawa, Luis G Paz-Ares, +12 more
1citations -
Circulating TP53 mutations are associated with early tumor progression and poor survival in pancreatic cancer patients treated with FOLFIRINOX2021 Therapeutic Advances in Medical Oncology article Medicine Pancreatic and Hepatic Oncology Research Open access
Fleur van der Sijde, Zakia Azmani, Marc G. Besselink, Bert A. Bonsing, Jan Willem B. de Groot, Bas Groot Koerkamp, +12 more
19citations -
Circulating tumour DNA dynamics predict recurrence in stage III melanoma patients receiving neoadjuvant immunotherapy2024 Journal of Experimental & Clinical Cancer Research article Medicine Cutaneous Melanoma Detection and Management Open access
Wei Yen Chan, Jenny Lee, Ashleigh Stewart, Russell J. Diefenbach, Maria Gonzalez, Alexander Maxwell Menzies, +4 more
30citations -
Clinical Activity of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumor Harboring Heterogeneous KIT/PDGFRA Mutations in the Phase III INVICTUS Study2021 Clinical Cancer Research article Medicine Gastrointestinal Tumor Research and Treatment Open access
Sebastian Bauer, Michael Charles Heinrich, Suzanne George, John Raymond Zalcberg, César Serrano, Hans A. J. Gelderblom, +11 more
46citations -
Quantitative modeling of tumor dynamics and development of drug resistance in non‐small cell lung cancer patients treated with erlotinib2024 CPT Pharmacometrics & Systems Pharmacology article Medicine Lung Cancer Treatments and Mutations Open access
Anyue Yin, G. Veerman, J. G. Coen van Hasselt, Christi M. J. Steendam, Hendrikus Jan Dubbink, Henk‐Jan Guchelaar, +4 more
6citations -
Mutational heterogeneity of imatinib resistance and efficacy of ripretinib vs sunitinib in patients with gastrointestinal stromal tumor: ctDNA analysis from INTRIGUE.2023 Journal of Clinical Oncology conference-abstract Medicine Gastrointestinal Tumor Research and Treatment
Sebastian Bauer, Robin L. Jones, Suzanne George, Hans A. J. Gelderblom, Patrick Schöffski, Margaret von Mehren, +13 more
16citations -
INSIGHT: A phase 3, randomized, open-label study of ripretinib vs sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib with KIT exon 11 + 17/18 mutations.
Michael Charles Heinrich, Jean‐Yves Blay, Ping Chi, Robin L. Jones, César Serrano, Neeta Somaiah, +7 more
1citations